NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Rhea-AI Summary

NanoViricides (NYSE:NNVC) reported Q3 2024 financial results with cash and equivalents of $3.87 Million and net property assets of $7.36 Million. The company's lead drug candidate NV-387, a broad-spectrum antiviral, is progressing toward Phase II clinical trials for multiple indications including MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71 million through ATM offering and has access to a $3 million credit line, though additional funding will be needed for planned Phase II trials. NV-387 has shown promising results in animal trials, potentially offering superior effectiveness compared to existing treatments for various viral infections.

Positive

• Successful completion of Phase Ia/Ib trial with no adverse events
• Strong preclinical results showing NV-387 superiority over existing treatments
• Broad-spectrum application potential across multiple viral infections
• Access to $3 million credit line from company founder

Negative

• Insufficient funding to continue operations through November 2025
• Cash position decreased from $4.8M to $3.87M quarter-over-quarter
• Ongoing need for additional capital raising
• Current liabilities increased from $1.36M to $1.63M

Insights

Financial Analyst

This 10-Q filing reveals significant financial details and operational plans. The company has $3.87M in cash and equivalents, down from $4.8M in June 2024, with $7.36M in net property assets. The burn rate is concerning, with $2.6M used in operations last quarter. While they've raised additional capital through ATM offerings and have access to a $3M credit line, the company explicitly states insufficient funding for operations through November 2025.

The company's market cap of $18.7M appears low relative to their assets and clinical progress, but the funding uncertainty creates significant risk. Their need for additional capital to support planned Phase II trials could lead to further dilution. The cash position, after accounting for liabilities, provides roughly $6M for operations, which may be insufficient for their ambitious clinical plans.

Medical Research Analyst

NV-387 shows promising broad-spectrum antiviral potential with notable advantages over existing treatments. Key differentiators include:

• Superior performance against RSV compared to current options in animal models
• Competitive results against approved drugs for influenza and poxviruses
• Novel mechanism targeting virus cell entry via sulfated proteoglycan mimicry
• Lower likelihood of viral resistance due to targeting essential cell entry mechanism

The completion of Phase Ia/Ib trials with no adverse events is positive, but the critical test will be Phase II efficacy trials. The focus on high-need indications like pediatric RSV and MPox shows strategic targeting of valuable market opportunities. However, the lack of secured funding for Phase II trials presents a significant execution risk.

SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).

We reported that, as of September 30, 2024, we had cash and cash equivalent current assets balance of approximately $3.87 Million. In addition, we reported approximately $7.36 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.63 Million. In comparison, as of June 30, 2024, we had cash and cash equivalent balance of approximately $4.8 Million, P&E assets of approximately $7.51 Million (after depreciation), and total current liabilities of approximately $1.36 Million.

The net cash utilized in the reported period for operating activities was approximately $2.6 million that included certain non-recurring expenditures including R&D expenditures in preparation for a Phase II clinical trial application of approximately $1 million. We raised approximately $1.71 million net of commission and certain expenses in an At-the-Market offering ("ATM") in the reported period.

Subsequent to the reporting period, we raised approximately $0.63 million net of commission and certain expenses in an At-the-Market offering ("ATM"). With this raise and an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan, we have approximately $7.6 million (approximately $6 million net of current liabilities) available for cash operational expenses going forward. As such, we reported that we do not have sufficient funding in hand to continue operations through November 14, 2025, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPOX infection in Central Africa and (ii) a Phase II clinical trial of NV-387 for RSV indication in the USA.

NV-387 - Progressing Towards Phase II Clinical Trial

We have made significant progress in the regulatory advancement of NV-387. A Phase Ia/Ib clinical trial in healthy subjects was completed with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial.

Additionally, we have made significant progress towards initiating Phase II clinical trial of NV-387 for the treatment of MPox infection in Central Africa. The MPox Clade 1/1b infection has been declared a Public Health Emergency of International Concern (PHEIC) by the WHO. Spillover cases have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as coronaviruses. The MPox Clade 1/1b has a substantially greater fatality rate than COVID, at 3-4%, and it has been disproportionately affecting pediatric populations.

There is currently no drug available for the treatment of MPox infection. A drug approved for Smallpox/Mpox and stockpiled by the US Strategic National Stockpile, namely tecovirimat (TPOXX®, SIGA), was found to be ineffective for the treatment of the MPox infection in a clinical trial co-sponsored by NIH/NIAID. A vaccine developed for Smallpox, Jynneos (Bavarian Nordic) is being deployed but is in short supply. Its clinical utility for MPox Clade 1/1b is not known.

NV-387 A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape

Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, Influenza, and Mpox/Smallpox.

In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.

NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche).

Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with or superior to the approved drug tecovirimat (TPOXX®, SIGA).

NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for COVID, Influenza and Poxviruses.

This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.

Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.

Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.

NV-387 Regulatory Strategy

In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. In addition to the Phase II clinical trial to assess effectiveness of NV-387 in treating MPox infections, we are also planning to advance NV-387 into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection.

We plan on advancing the regulatory processes for NV-387 registration for other indications including Influenza and COVID via partnerships and non-dilutive funding.

As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity-based funding.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

CONTACT:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on accesswire.com

FAQ

What were the results of NanoViricides (NNVC) Phase Ia/Ib trial for NV-387?

The Phase Ia/Ib clinical trial in healthy subjects was completed by December 2023 with no adverse events reported. The company is currently awaiting the final report.

How much cash does NanoViricides (NNVC) have as of September 30, 2024?

NanoViricides reported cash and cash equivalent current assets of approximately $3.87 Million as of September 30, 2024.

What are the planned Phase II trials for NanoViricides' (NNVC) NV-387?

NanoViricides plans two Phase II trials: one for MPOX infection in Central Africa and another for RSV indication in the USA.

How does NanoViricides' (NNVC) NV-387 work against viruses?

NV-387 is designed to attack virus particles by mimicking sulfated proteoglycan (S-PG), targeting viruses that use heparan sulfate proteoglycans for cell entry.